Senior Director, Global Access Strategy & Pricing, Vepdegestrant & Breast Cancer

The Global Access Strategy and Pricing (GASP) Senior Director role directly impacts the ability to achieve business objectives by providing strategic guidance on access, pricing, optimal reimbursement, launch sequencing, patient value, and evidence generation for Vepdegestrant globally in preparation for launch and with consideration for long term value given subsequent indications.

Vepdegestrant is an Alliance product with Arvinas.  

In collaboration with the asset development team, and Arvinas partners, the Senior Director will formulate market access and pricing strategies, including launch GPA, and conduct/oversee generation and synthesis of global payer insights, recommendations for clinical trial design for subsequent indications and oversee the development of financial models to evaluate the impact of lifecycle indications and combinations within the Breast cancer portfolio.   

This position will function with a ‘One Global Access and Value’ mindset and work in a closely aligned manner with the other GAV colleagues (USMA, HV&E). This role will lead the advancement of the integrated value and access strategy, In partnership with the cross functional team and Alliance partners, that is aligned to the brand strategy and optimizes the long-term value of Vepdegestrant within the context of the breast cancer franchise. The position reports to the GASP Breast Cancer Team Lead within GAV.
 

ROLE RESPONSIBILITIES

• Independently lead generation of payer insights and translation into clear and cohesive integrated value and access, pricing and evidence generation strategies for key markets to support Vepdegestrant and breast cancer.
• Provide subject matter expertise and drive critical strategic discussions at Senior Leadership forums.
• Lead Global cross functional and local preparation of Vepdegestrant EU JCA readiness in close partnership with HV&E
• Oversee market access and pricing strategy development and implementation to support brand strategies within the context of the breast cancer portfolio franchise and product positioning.
• Influence and shape breast cancer lifecycle management leveraging expertise in access and price optimizing strategies.
• Deliver clear recommendations relating to payer strategy, pricing and reimbursement, evidence generation, data collection and value proposition.
• Achieving the above will variously require the formation of leadership and/or participation in virtual cross functional teams including representing GAV at the GPT, and at Alliance meetings. When necessary, convene and coordinate taskforce deployments related to specific asset threats and opportunities.

Generate & synthesize payer insights

• Maintain in-depth understanding of payer regulations, needs of all types of payers (e.g. HTA agencies, institutions and patients) in key Pfizer markets.
• Knowledgeable about US Oncology Access & Pricing Landscape, IDM Markets, China, HTA/Payer requirements and EU JCA.
• Lead assessment and communication of external access trends to anticipate potential challenges and opportunities for Vepdegestrant
• Gather and synthesize feedback for development programs with health technology assessment agencies, payers, and relevant patient associations.

Develop payer value proposition and drive market access strategy

• Develop clear and cohesive access, pricing and evidence generation strategy to optimize value of Vepdegestrant through the Access Matrix Team (AMT). 
• Lead discussions with Country Health & Value and Payer Channel Access Leads at critical junctures to ensure local insights are integrated into global plans that optimize long-term value for Vepdegestrant within the context of the breast cancer franchise, including input into clinical development plans, market access and pricing strategies and recommendations, early HTA advice, early economic models, and evidence generation plans via the Integrated Value & Access Plan.
• Lead alignment efforts with Commercial, BAI, Clinical, Medical, Asset teams, and the Alliance to ensure clinical trial design and commercial strategies reflect payer insights and align with Bold Moves in order to maximize value of Vepdegestrant. 
• Lead discussions and seek early buy-in from senior leadership on price and market access strategy and recommendations to support key business decision points.
• Drive development of the value proposition and value-based agreement strategy and seek buy-in from cross-functional stakeholders.
• Develop launch deliverables and training , including Pfizer and Alliance aligned GPA and US Pricing & Market Access Strategy, Launch Readiness, Mock Negotiations
• Partner with HV&E to influence clinical trial design recommendations (e.g. endpoints, comparators, PROs), development of early economic model